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Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the 
brain and the spinal cord. Previous proteomic evidence revealed that the content of certain peptide fragments 
including Vgf-derived peptide aa 398-411 (Vgf398-411) of the precursor Vgf protein in the cerebral spinal fluid (CSF) 
correctly identified patients with ALS from normal and disease controls. Using quantitative ELISA immunoassay 
we found that the CSF levels of Vgf decreases with muscle weakness in patients with ALS. In SOD1 G93A 
transgenic mice, loss of full-length Vgf content in CSF, serum and in SMI-32 immunopositive spinal cord motor 
neurons is noted in asymptomatic animals (approximately 75 days old) and continues to show a progressive de-
cline as animals weaken. In vitro studies show that viral-mediated exogenous Vgf expression in primary mixed 
spinal cord neuron cultures attenuates excitotoxic injury. Thus, while Vgf may be a reliable biomarker of pro-
gression of muscle weakness in patients with ALS, restoration of Vgf expression in spinal cord motor neurons 
may therapeutically rescue spinal cord motorneurons against excitotoxic injury. 
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Introduction 
Vgf nerve growth factor inducible peptide, a non 
acronymic peptide is a member of the chromo-
granin/secretogranin family of proteins. These pro-
teins are stored in large dense core vesicles (LDCVs) 
located in neuroendocrine, endocrine and neuronal 
cells. LDCVs are released in response to depolarization 
and other stimuli. Vgf is widely expressed in the cen-
tral nervous system including spinal cord motorneu-
rons. We previously reported that decreased CSF lev-
els of certain peptide fragments including Vgf398-411 
correctly identify patients with ALS from normal and 
disease controls. [1] The biological role of Vgf is in-
completely understood, [2-13] although recent studies 
demonstrate significant endocrine, metabolic and 
anti-depressant effects of Vgf-derived peptides. [14-17]  
The present study suggests that Vgf may be a 
useful biomarker to monitor ALS onset and clinical 
progression and that therapeutic preservation of Vgf 
might neuroprotect spinal cord motorneurons against 
excitotoxic injury in ALS.  
Methods 
Human subjects 
CSF from normal subjects (n=21) and ALS pa-
tients (n=17) were used for ELISA. ALS patients were 
classified as having either definite or probable ALS 
according to the WFN El-Escorial diagnostic criteria. 
[18] ALS patients were classified according to number 
of segments with clinical weakness, from a total of 3 
segments of the central nervous system (cranial, cer-
vical, and lumbar). Clinical weakness identified only in 
one segment occurred in 10 patients; weakness in two 
segments was identified in 7 patients. The total score 
on manual muscle testing (MMT) measured severity of 
muscle weakness. Five muscle groups in each of the 
four limbs were examined and graded according to the 
standard Medical Research Council (MRC) criteria, on 
a scale from 0 (no movement) to 5 (full strength against 
maximal resistance). The total possible normal score 
on this examination is 100. All CSF samples used were 
derived from comparable fractions (e.g. 20–25 ml), to 
limit variability from rostro-caudal concentration gra-
dients. Following collection, samples were gently 
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mixed, divided into aliquots, and immediately frozen 
in dry-ice and stored at –80° C. Written informed con-
sent, approved by the Mount Sinai School of Medicine 
Institutional Review Board (IRB) on November 3, 2004, 
was obtained from all subjects. 
ELISA assays 
hVgf ELISA, microtiter plates were coated with 
2-mg/mL goat polyclonal anti-Vgf antibody (R15) 
(Santa Cruz Biotech, Santa Cruz, CA), which recog-
nizes the C-terminal epitope of Vgf. Unoccupied 
binding sites on the plates were blocked by incubation 
with casein. Samples and standards were applied in 
duplicate and incubated overnight at 4°C. Following 
the Vgf capture phase, the plates were reacted with 
rabbit anti-Vgf antibody (#9130 against Vgf78-340) [19] 
followed by incubation with a reporter antibody 
(HRP–conjugated anti–rabbit IgG, Santa Cruz Biotech, 
CA). The assay was developed using a stabilized HRP 
substrate. All samples were analyzed in the linear 
range of the ELISA using over-expressed human Vgf 
as a standard.  
Assessment of motor function 
Mutant G93A SOD-1 transgenic mice were tested 
on the accelerating Rotarod (7650 Ugo Basile Biol. Res. 
App., Comerio, Italy) as described previously. [20-21] 
Mice were tested 3 times a week beginning at ~ 70 
days, until the transgenic mice could no longer per-
form the tests. Before testing, mice underwent a 
one-week training period wherein they were intro-
duced to the apparatus and handled by the operator 
daily. Testing was conducted during the last 4 hours of 
the day portion of the light cycle in an environment 
with minimal stimuli (noise, movement, changes in 
light or temperature) for a maximum time maintained 
on the rod by each mouse of 240 seconds. 
Western blot and protein expression analysis 
Frozen brain and spinal cord samples were first 
pulverized on dry ice, homogenized in cell lysis buffer 
(20 mM Tris/HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 
1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyro-
phosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 
1 μg/ml leupeptin, and 1mM phenylmethyl sulphonyl 
fluoride), and sonicated for 2 min at 4ºC. The lysates 
were centrifuged at 2,500 x g for 15 min at 4ºC to re-
move nuclei and cell debris. Samples were then sepa-
rated (50-100 μg protein loaded per lane) on 12% 
SDS-PAGE, transferred to a PVDF membrane (Bio-
Rad), and detected with rabbit anti-Vgf antibody 
(Ab5901, 1:1000).[22] On the same membrane, 
β-tubulin (rat anti-β tubulin, 1:5000, Sigma, St. Louis, 
MO) was used to control sample loading and to nor-
malize Vgf immunoreactivity.  
Immunocytochemistry  
For semiquantitative assessment of Vgf in spinal 
cord motorneurons, immunohistochemistry was per-
formed as previously reported [21] with minor modi-
fications. Briefly, spinal cord tissue sections were 
treated with an antibody against Vgf (rabbit anti rat 
monoclonal D20, 1:1000, Santa Cruz, CA) or against 
SMI-32 (rabbit polyclonal, 1:200 dilution; Santa Cruz 
Biotechnology, Inc.) labeled with Zenon Alexa Fluor 
594 (mouse IgG labeling kit; Molecular Probes Inc.) at 
25°C for 1 h. Furthermore, the sections were treated 
with the monoclonal antibody against Vgf (rat mono-
clonal, 1:100 dilution; Santa Cruz Biotechnology, Inc.) 
labeled with Zenon Alexa Fluor 488 (mouse IgG la-
beling kit; Molecular Probes Inc.) at 25°C for 1 h. The 
fluorescence emitted was observed through each ap-
propriate filter on a fluorescence microscope (BX51; 
Olympus) and digitally photographed using a cooled 
charge-coupled-device camera (model VB-6000/6010; 
Keyence Co.). In control studies run in parallel, tissue 
sections were also stained with anti- glial fibrillary 
acidic protein (GFAP), a glial marker, or and anti 
NeuN, a neuronal marker, as previously described.[21]  
Stereology of SMI-32 immunopositive neurons  
For stereological assessment of SMI-32 (a 
non-phosphorylated neurofilament epitope) immu-
noreactive spinal cord motorneurons, 10 serial coronal 
sections (12 μm thick) were cut 350 μm apart through 
the lumbar (L3 to L5) spinal cord of each animal. The 
sections were mounted onto positively charged glass 
slides (Superfrost Plus, Fisher Scientific) and immu-
nostained using a commercially available rabbit 
anti-rat SMI-32 antibody (D20, 1:1000, Santa Cruz, 
CA). SMI-32 immunopositive neurons were counted 
from digitised images (200X) within the ventral horns 
under fluoresce microscopy. These counts were within 
a homogenous structure, making the tenets of 
stereology valid. SMI-32-stained neurons were 
counted using the Neurolucida system at a magnifica-
tion of 250X in both ventral horn areas from six L3-L5 
tissue sections of the spinal cord of each mouse. All 
SMI-32 immunoreactive neurons were counted from 
within the ventral horn below a lateral line across the 
spinal cord from the central canal. Correction for tissue 
section thickness was made in all specimens. 
For stereological analysis, 10 serial coronal sec-
tions (12μm thick) were cut 350μm apart through the 
lumbar (L3 to L5) spinal cord of each animal (WT con-
trols; n=6).  
Semiquantitative Vgf quantification in spinal cord 
motorneurons  
The immunostaining densities were digitized 
with a high-resolution fluorescence charge-coupled--
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device camera (Sony, Tokyo, Japan) and 
semi-quantified using Bioquant computer-assisted 
densitometry (Biometrics, Nashville, TN). Fluores-
cence camera aperture and focus were adjusted to 
provide an optimal image. The overall illumination 
was also adjusted so that the distribution of relative 
values fell within the limits of the system avoiding a 
floor or ceiling effect. Once established, the setting 
remained constant for all the images acquired for all 
the ICC experiments. Therefore, when all the parame-
ters were fixed, only tissue staining intensities influ-
enced the measured values. Average value density 
measurements from individual Vgf immunoreactive 
dorsal spinal cord neurons, reflecting immunostaining 
intensity, were made on digitized images by delimiting 
the cellular area of interest free hand, using predeter-
mined criteria to define the region of interest. The 
immune intensity of the cellular Vgf encompassing the 
L3-L5 regions of spinal cord were semi-quantified 
from approximately 6 to 8 frames per spinal cord tis-
sue sections; about 3 to 10 neurons per frame were 
randomly quantified. The technician who performed 
these measurements had no knowledge of the study 
groups. To normalize any unevenness in lighting 
across the field of view; background values were de-
termined over the white matter area of each individual 
tissue section and automatically subtracted from the 
values over unstained spinal cord motorneurons. The 
optical density of cellular Vgf immunostaining in spi-
nal cord dorsal neurons was expressed using arbitrary 
units. 
Mouse Vgf radio immuno assay (RIA) 
C-terminal specific Vgf antibody (ab5901) was 
used in RIA analysis as previously described [22] to 
detect full-length Vgf and processed Vgf peptides 
containing the C-terminus. AQEE30 peptide was ra-
diolabelled with I125 at ~2000 Ci/mmol specificity by 
GE-Healthcare (Woburn, MA). Briefly, samples or 
standard AQEE30 peptide, from 30-3000 fmol, were 
incubated with anti-Vgf (AQEE30) antibody (1:3000 
dilution) in 200 µl RIA buffer (50mM Tris-Cl, 0.1% 
BSA, 0.1% Triton-X100, 0.1% Gelatin, 0.02% Sodium 
Azide) at 4°C overnight. After adding 100 µl of 
I125-AQEE30 tracer (10,000 cpm) at 4°C overnight, the 
antibody complex was precipitated with 100 µl of goat 
anti rabbit IgG and 10 µl of normal rabbit serum 
(Peninsula Laboratories Inc., San Carlos, CA) dis-
solved in RIA buffer. After incubating at room tem-
perature for 1.5 hr, the reactions were stopped by ad-
dition of 250 µl ice-cold termination buffer (50mM 
Tris-HCl, 0.1% Triton-X100, 0.02% sodium azide). The 
supernatants were aspirated after centrifugation at 
3700 x g for 20 min. Vgf-specific radioactivity was 
quantified using a CobraII Auto γ Counter (PerkinEl-
mer, Wellesley, MA). 
Adeno-Vgf viral constructs 
The replication-defective recombi-
nant-adeno-expression virus was generated using the 
Adeno-X expression system following the manufac-
turer’s procedure (Clontech, CA). Briefly, mouse Vgf 
cDNA (Salton, unpublished data) was isolated via Xba 
I-Apa I restriction cleavage, and cloned into the 
NheI-ApaI sites of a pShuttle vector to generate the 
expression cassette under regulation of the cytomega-
lovirus (CMV) promoter. The cDNA constructs were 
sequence-confirmed, and the expression cassette was 
then transferred from the pShuttle construct into puri-
fied Adeno-X viral DNA via I-CeuI and PI-SceI sites.  
The recombinant viral cDNA construct was con-
firmed by nucleotide sequencing, and the recombinant 
virus was packaged by infecting the PacI linearized 
recombinant viral DNA into human embryonic kidney 
(HEK)-293 cells (Clontech, CA). The resulting recom-
binant virus was further propagated in HEK 293 cells, 
and a viral titer was determined by tissue culture in-
fectious dose 50 (TCID50). [23] A control Lac-Z re-
combinant adenovirus expressing the β-galactosidase 
gene product was prepared using an identical strategy. 
HEK 293 cells were cultured in DMEM medium sup-
plemented with 10% fetal calf serum (FBS) and 100 
U/ml penicillin-streptomycin (Gibco, NY).  
Spinal cord neuron cultures 
Mixed spinal cord cultures were prepared ac-
cording to Zhao et al.[21]. Briefly, spinal cord cultures 
were prepared from E14 embryos dissected from 
pregnant wild type females that had been mated with 
SOD1-G93A transgenic males. Each spinal tube was 
dissected, removed from the meninges, and incubated 
for 10 min in 0.25% trypsin/EDTA at 37°C and then 
dissociated by gentle trituration with a fire-polished 
Pasteur pipette. The cell suspension was plated in 
D-MEM/F12 supplemented with 10% FBS on a poly D 
lysine-coated 96 well plate at a density of 105 
cells/well. After 30 min, the medium was replaced 
with Neurobasal media supplemented with 2% B-27, 
0.5 mM glutamine, and 1% penicillin/streptomycin. 
Cultures were maintained under standard conditions 
as previously reported [21].  
Excitotoxicity studies in vitro  
In viral expression studies, 5 day-old cultures 
were replaced with fresh Neurobasal medium con-
taining Adeno-LacZ or Adeno-Vgf constructs, at a 
multiplicity of infection (MOI) of 5, and culture me-
dium was replaced again 3 days thereafter. For exci-
totoxicity studies ~ 8-day-old spinal cord cultures were 
challenged with the glutamate receptor agonists 
AMPA (5 µM) and NMDA (20 µM) for 48 hours. 
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Neurotoxicty was assessed by LDH assay kit according 
the manufacturer’s instructions (Promega Corp 
Madison, WI), or using an MTT 
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] assay.[24]  
Statistical analysis 
Statistical analyses were performed using Sig-
maStat (version 3.0, SPSS Inc., Chicago, IL). Inde-
pendently measured t-tests were used to compare 
endpoints between control and experimental groups in 
either clinical or preclinical studies. ANOVA tests 
among groups were followed, when significant, by the 
Student-Newman-Keuls multiple comparison tests. 
The Student-Newman-Keuls test was chosen for 
post-hoc multiple comparisons due to its generally 
higher sensitivity compared to the Bonferroni test. In 
all tests, results with probability values less than 0.05 
were considered statistically significant. Presented 
data are shown as mean ± SEM, unless otherwise 
noted. The receiver operating characteristic (ROC) 
curve was used to relate “sensitivity” and “specific-
ity,” or sensitivity at a given specificity for providing 
cut-off values, as previously described [1]. The null 
hypothesis was rejected at the 0.05 level in all analyses.  
Results 
CSF Levels of Vgf correctly diagnose ALS and as-
sociates with clinical severity 
Quantitative ELISA assay revealed that the de-
creased CSF levels of total full-length Vgf (P<0.05), 
correctly diagnosed ALS patients with 77% sensitivity 
and 87% specificity based on receiving operating 
characteristic (ROC) analysis (Figure 1A). Vgf CSF 
content decreased as a function of progression of 
muscle weakness characterized by an increasing 
number of affected muscle (segments) assessed by 
manual muscle testing (P<0.05) (Figure 1B).  
 
 
Figure 1. Full length Vgf content in CSF in ALS. In A, full-length Vgf was assessed by quantitative ELISA assays; in B, Vgf 
content decreased as a function of progression of muscle weakness assessed by manual muscle testing revealing an increased number 
of affected muscle (segments). Quantitative muscle testing was based on the MRC clinical grading system, out of a total of 100 
possible points. ROC analysis was carried out to determine the sensitivity and specificity of Vgf in dissecting control vs. ALS 
subjects. Values are expressed as percent of control level (mean ± SEM; * 2-tailed t-test, p<0.05). Inset, Vgf protein sequence used to 
raise Vgf antibodies for ELISA assays (see Materials and Methods for more information).  
 
Decreased Vgf content In CSF and serum precedes 
onset of ALS-type muscle weakness assessed by 
rotarod-assays.  
In our laboratory setting, G93A mutant 
SOD-1ALS mice develop muscle weakness by ~90 
days of age (Figure 2A). The severity of motor im-
pairment progresses to paralysis by ~130 days of age, 
followed by sacrifice.[1] No detectable change in Vgf 
content in CSF and serum of G93A SOD-1 ALS mice 
was found in ~35 days old G93A SOD-1 ALS mice, 
relative to age-, gender-, and strain-matched wild-type 
littermates (Figure 2B,C).  
 
Reduction in Vgf content in the CSF (F1,7793=4.913, 
P=0.0288 for age, F7,23660=2.131, P=0.0466 for Vgf con-
tent) and in the serum (F1,19840=5.4573, P=0.0345 for age, 
F7,34510 =3.945, P=0.0487 for Vgf content) in ~75 days old 
G93A SOD-1 mice was found to precede the onset of 
muscle weakness assessed by rotarod assay that nor-
mally occurs at ~90 days, relative to age-, gender-, and 
strain-matched wild-type littermates.  
Serum and CSF content of Vgf continued to de-
crease up to ~130 days of age when G93A-SOD1 ALS 
mice are characterized by near complete paralysis, 
relative to gender-matched WT littermates (Figure 2B, 
C).  
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Vgf immunoreactive material in the lumbar (L3 to 
L5) spinal cord colocalizes with SMI-32 im-
munopositive motorneurons and decreases as a 
function of age progression in SOD-1 ALS mice.  
In the lumbar L3 to L5 region of spinal cord the 
distribution of Vgf immunoreactive material colocal-
ized with SMI-32 immunoreactive spinal cord neurons 
(Figure 3A, panels 2-4). No detectable Vgf im-
munopositive signal was found to co-localize with 
NeuN immunoreactive neurons in the same spinal 
cord region (Figure 3B, panels 2-4), nor was there Vgf 
immunoreactive signal that co-localized with GFAP 
immunopositive astrocytes (data not shown). 
 
Figure 2. Decreased Vgf content in the CSF and serum precedes ALS-type motor impairment assessed by rotarod assay. In 
A, ALS-type muscle weakness in mutant G93A SOD-1 as a function of clinical progression (age). In B,C, decreased Vgf levels in 
CSF and in serum respectively precedes ALS-type muscle weakness in ~90 day-old symptomatic mutant G93A-SOD-1 mice and 
continue to decline as a function of progression of ALS-type clinical disease. Values are expressed as mean ± SEM; n=4-5 per group; 
2-way ANOVA. No detectable muscle weakness was found in age-gender matched WT controls at any time examined (not shown).  
 
 
Figure 3. Vgf immunoreactive material in the lumbar spinal cord co-localizes with SMI-32 immunopositive motorneurons and 
decreases as a function of age progression of SOD-1 ALS mice. In A, Vgf immunoreactive material is selectively localized within 
the nuclear region of SMI-32 immunoreactive spinal cord neurons. In B, no detectable Vgf co-localization with NeuN immunore-
active neurons. In C, Vgf immunoreactive material in spinal cord motorneurons as a function of age. In D, SMI-32 spinal cord 
motorneurons in the L3-L5 region of spinal cord in ~130 days old mutant G93A-SOD1 ALS mice. Values are expressed as mean ± 
SEM; n=4-5 per group; In C,*2-way ANOVA; in D, *p<0.05 by 2-tailed t-test 
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Survey of Vgf content assessed immunocyto-
chemically revealed that Vgf immunoreactive material 
in spinal cord motorneurons is already decreased in 
~75 day old asymptomatic SOD-1 G93A-SOD1 ALS 
mice and continue to decrease as a function of pro-
gression of ALS-type muscle weakness up to ~130 
days of age (Figure 3C)(F1,19840=14.28, P=0.0003 for age, 
F7,34510 =3.549, P=0.0018 for Vgf content), relative to 
age-, gender-, and strain-matched wild-type litter-
mates.  
The loss of Vgf immmunoreactive signal in 
SMI-32 spinal cord motorneurons in the L3-L5 region 
of spinal cord in ~130 days old mutant G93A-SOD1 
ALS mice overlaps quantitatively with the loss in 
SMI-32 immunoreactive motorneurons assessed 
stereologically in the same tissue sections (Figure 3D), 
relative to age-, gender-, and strain-matched wild-type 
littermates.  
Exogenous adenoviral Vgf expression protects 
G93A SOD1 mixed spinal cord neurons against 
excitotoxic injury.  
Total full-length mouse (m)vgf protein was ex-
pressed in ~8 days old primary mix mutant G93A 
SOD-1 spinal cord neuron cultures derived from E14 
mouse embryos by infection with an adenoviral Vgf 
(Ad)-Vgf at 5 MOI.  
Under this experimental condition, Ad-mVgf ex-
pression significantly increased intracellular Vgf and 
secreted full length Vgf protein (85 kDa) in the condi-
tioned medium, relative to parallel Lac-Z infected 
cultures (5 MOI) (Figure 4, and Figure 4 inset (not 
shown)), as assessed by western blot 48 hrs after infec-
tion. Next we explored the influence of exogenous Vgf 
expression in response to excitotoxic neuronal injury.  
 
Figure 4. Exogenous adenoviral mVgf expression attenuates 
excitotoxicity in mixed cultures of spinal cord neurons. Neuron 
cultures were infected with Adeno (Ad)-Vgf or Ad-LacZ viral 
constructs at 5 MOI for 72 hrs, and then treated with AMPA (5 
µM), NMDA (20 µM) for 48 hrs while cell viability was as-
sessed by LDH. Values are expressed as mean ± SEM as % of 
control (CTL) group; n=3 independent cultures per group; 
*P<0.05, **P<0.01; Ad-Vgf treatment vs. Ad-Lac-Z infected 
controls.  
We found treatment of control Lac-Z infected (5 
MOI) primary mixed spinal cord neurons with gluta-
mate receptor agonist AMPA (5 µM) or NMDA (20 
µM), results in significant 30-40% loss in cell viability 
relative to untreated Lac-Z infected cultures (P<0.01; 
P<0.05, respectively), as assessed by LDH cell viability 
assay, 48 hr after treatment (Figure 4). 
We found that preventative expression of Ad-Vgf 
in primary mix mutant G93A SOD-1 spinal cord neu-
ron cultures for 48 hrs resulted in significant protection 
against AMPA or NMDA mediated excitotoxic injury, 
as assessed by a neuronal viability assay 48 hr follow-
ing drug treatment (Figure 4). 
Discussion 
Our study demonstrates that reduced levels of 
full-length Vgf content in the CSF of ALS patients may 
be a useful measure of disease progression, as assessed 
by scores of muscle strength. Consistently, in experi-
mental studies we found that Vgf content in the CSF, 
serum and spinal cord motorneurons is a specific pre-
dictor of onset and progression of clinical motor im-
pairment. Thus, Vgf could provide a biological index 
to predict and monitor the development of motor im-
pairment in ALS before onset of clinical disease. Our 
study supports the hypothesis that restoring Vgf ex-
pression in spinal cord motor neurons could thera-
peutically benefit clinical ALS.  
The mechanism(s) that underlie the relationship 
between mutations in the SOD-1 gene and the patho-
genesis of sporadic ALS are uncertain. However, ex-
perimental evidence suggests that mitochondrial dys-
function/degeneration resulting in abnormal energy 
metabolism are important factors in the evolution of 
the disease in several SOD-1 mutant mouse models of 
ALS, including the G93A-SOD1 ALS mice used in this 
study. [25-30]  
Evidence suggests that both mutant SOD-1 ALS 
[3] and Vgf knockout [5,31,32] mice similarly display 
abnormal energy expenditure features supporting the 
hypothesis that reduced Vgf levels in an ALS model 
mice could contribute to the lean, hypermetabolic state 
that eventually could negatively influence clinical 
disease in ALS. Thus our study for the first time tenta-
tively supports the hypothesis that a mechanism 
thorough which abnormal metabolism may ultimately 
influence ALS pathogenesis is through mechanisms 
involving reduced expression of Vgf. This evidence is 
of high interest to this study especially in view of pre-
vious reports suggesting that sporadic ALS patients 
can be hypermetabolic with decreased fat mass,[25] a 
phenotype resembling that found in mutant 
G93A-SOD1 ALS mice.[3]  
We found that exogenous viral expression of Vgf 
neuroprotects primary mixed spinal cord neurons 
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against excitotoxicity, which is a pathogenic feature in 
ALS.[20] This observation tentatively suggests that 
reduced levels of Vgf expression in spinal cord mo-
torneurons in ALS SOD-1 ALS mice could mechanis-
tically promote neurodegeneration by unleashing 
NMDA and AMPA excitotoxic injury. Thus a mecha-
nism by which abnormal energy metabolism may have 
an influence on clinical ALS is through depletion of 
Vgf neuroprotection against spinal cord motorneuron 
excitotoxic injury. 
Collectively our study suggests that reduced Vgf 
content in the serum, in the CSF, and in spinal cord 
motorneurons may be a biological diagnostic index for 
ALS. It remains to be directly tested whether restoring 
Vgf expression in spinal cord motor neurons thera-
peutically rescues the ALS phenotype.  
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